NCT06310343View on ClinicalTrials.gov

ADAs to Alemtuzumab

Active, not recruitingOBSERVATIONAL

Enrollment

15

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Multiple Sclerosis

Interventions

DRUG

Alemtuzumab

Licensed dose

Trial Locations (1)

Unknown

Barts Health NHS Trust, London

All Listed Sponsors

lead

Queen Mary University of London

OTHER